Table 5.
Correlation between inflammatory markers and tumor characteristics.
| pN | Stage | |||||||
|---|---|---|---|---|---|---|---|---|
| pN0 | pN1 | pN2 | p-Value * | I | II | III | p-Value * | |
| N (%) | N (%) | N (%) | N (%) | N (%) | ||||
| HALP | ||||||||
| <32.16 | 44 (67.7) | 13 (20.0) | 8 (12.3) | 27 (40.9) | 20 (30.3) | 19 (28.8) | ||
| ≥32.16 | 143 (76.1) | 20 (10.6) | 25 (13.3) | 0.47 | 118 (61.8) | 37 (19.4) | 36 (18.8) | 0.008 |
| dNLR | ||||||||
| <2.67 | 75 (75.8) | 12 (12.1) | 12 (12.1) | 63 (62.4) | 21 (20.8) | 17 (16.8) | ||
| ≥2.67 | 112 (72.7) | 21 (13.6) | 21 (13.6) | 0.62 | 82 (52.6) | 36 (23.1) | 38 (24.4) | 0.09 |
| PLR | ||||||||
| <196.1 | 158 (76.7) | 23 (11.2) | 25 (12.1) | 126 (60.3) | 45 (21.5) | 38 (18.2) | ||
| ≥196.1 | 29 (61.7) | 10 (21.3) | 8 (17.0) | 0.08 | 19 (39.6) | 12 (25.0) | 17 (35.4) | 0.004 |
| SII | ||||||||
| <723.3 | 134 (77.9) | 18 (10.5) | 20 (11.6) | 113 (64.6) | 34 (19.4) | 28 (16.0) | ||
| ≥723.3 | 53 (65.4) | 15 (18.5) | 13 (16.0) | 0.08 | 32 (39.0) | 23 (28.0) | 27 (32.9) | <0.0001 |
| ALI | ||||||||
| <34.86 | 57 (67.9) | 14 (16.7) | 13 (15.5) | 38 (44.7) | 24 (28.2) | 23 (27.1) | ||
| ≥34.86 | 130 (76.9) | 19 (11.2) | 20 (11.8) | 0.18 | 107 (62.2) | 33 (19.2) | 32 (18.6) | 0.02 |
HALP: hemoglobin, albumin, lymphocyte, and platelet score; dNLR: derived neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; SII, systemic immune-inflammation index; ALI: advanced lung cancer inflammation index. * Mantel–Haenszel test for trend.